No Data
No Data
Huiyu Pharmaceutical Unit Gets Nod to Market Three Cancer Drugs in Uzbekistan
Shareholder Yang Bo's shareholding in Huiyu Pharmaceutical (688553.SH) has reduced to 5%.
Huayu Pharmaceutical (688553.SH) announced that on June 27, 2024, the company received a letter from shareholder Yang Bo...
Express News | Shareholder Yang Bo reduced its shareholding to below 5% at Huiyu Pharmaceuticals.
Express News | Huayu Pharmaceutical: Three products, including Docetaxel Injection, have obtained market approvals in Uzbekistan.
France Grants Marketing Approval for Huiyu Pharma's Osteoporosis Injection
Huayu Pharmaceuticals (688553.SH): Zoledronic acid injection has obtained French trading license.
On June 19th, Gelunhui reported that its wholly-owned subsidiary, Seacross Pharma (Europe) Ltd., recently received approval from the French National Agency for Medicines and Health Products Safety to market the company's zoledronic acid injection. Zoledronic acid injection is mainly used to treat osteoporosis in postmenopausal women and adult men, osteoporosis induced by long-term glucocorticoid therapy in postmenopausal women and adult men, and adult Paget's disease of bone (osteitis deformans).
No Data